IPO News | Puqi Pharmaceutical's second listing on the Hong Kong Stock Exchange

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on July 24, Beijing Puqi Pharmaceutical Technology Co., Ltd. (abbreviation: Puqi Pharmaceutical) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CITIC Securities and Civil Bank Capital as co-sponsors. The company submitted a Hong Kong stock prospectus on January 21, 2026. According to the prospectus, Puqi Pharmaceutical is a biotechnology company focused on treating immune inflammatory diseases through targeted therapy delivery through topical delivery. The company's candidate product portfolio includes four self-developed innovative drug candidates and five generic drug candidates, covering indications such as atopic dermatitis, allergic rhinitis, pruritus, autoimmune kidney disease, and glaucoma.

The company's core product, PG-011 (prumexitinib), is a small-molecule JAK1/2 inhibitor. Currently, two dosage forms, prumexitinib gel and nasal spray, are mainly being developed to treat mild to moderate atopic dermatitis and moderate to severe hyperallergic rhinitis, respectively. Among them, phase IIb/III clinical trials of prumexitinib gel for the treatment of atopic dermatitis in adults and adolescents aged 12 to 17 have been completed, and the marketing application for the new drug was accepted by the State Drug Administration in February 2026. According to Frost & Sullivan data, China's atopic dermatitis drug market is RMB 13.2 billion in 2025 and is expected to increase to RMB 25.4 billion in 2028; the market size of allergic rhinitis drugs in China during the same period is RMB 5.3 billion, which is expected to increase to RMB 10 billion in 2028.

IMG_1536.jpeg